| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Douglas B Sawyer | |
| Laura Pentassuglia | |||
| P2860 | cites work | Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase | Q22009917 |
| Integrin-regulated FAK-Src signaling in normal and cancer cells | Q24300271 | ||
| Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes | Q24308695 | ||
| Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart | Q24316150 | ||
| The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system | Q24601534 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Cloning and characterization of GRB14, a novel member of the GRB7 gene family | Q28115522 | ||
| The human neuregulin-2 (NRG2) gene: cloning, mapping and evaluation as a candidate for the autosomal recessive form of Charcot-Marie-Tooth disease linked to 5q | Q28137639 | ||
| Roles of Meltrin beta /ADAM19 in the processing of neuregulin | Q28140324 | ||
| FAK integrates growth-factor and integrin signals to promote cell migration | Q28144169 | ||
| Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity | Q28212034 | ||
| Restoration of resting sarcomere length after uniaxial static strain is regulated by protein kinase Cepsilon and focal adhesion kinase | Q28245154 | ||
| A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester | Q28251593 | ||
| RGD and YIGSR synthetic peptides facilitate cellular adhesion identical to that of laminin and fibronectin but alter the physiology of neonatal cardiac myocytes | Q28282427 | ||
| Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling | Q28283670 | ||
| Neuregulin-1 promotes formation of the murine cardiac conduction system | Q28507021 | ||
| Isolation and characterization of macrovascular and microvascular endothelial cells from human hearts | Q72383141 | ||
| Cultivation and characterization of micro- and macrovascular endothelial cells from the human heart | Q72737666 | ||
| Functional role of c-Src in gap junctions of the cardiomyopathic heart | Q73082814 | ||
| Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme | Q73204078 | ||
| Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis | Q73278904 | ||
| Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis | Q73504931 | ||
| Integrin alpha2beta1 recognizes laminin-2 and induces C-erb B2 tyrosine phosphorylation in metastatic human melanoma cells | Q73656384 | ||
| New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays | Q77220709 | ||
| Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes | Q79148148 | ||
| Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy | Q79162330 | ||
| Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes | Q79367416 | ||
| Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes | Q80074305 | ||
| HB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways | Q80229741 | ||
| Expressional reprogramming of survival pathways in rat cardiocytes by neuregulin-1beta | Q80411209 | ||
| Endothelin-1 and Neuregulin-1 convert embryonic cardiomyocytes into cells of the conduction system in the mouse | Q81505289 | ||
| Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor | Q28509287 | ||
| Cysteine-rich domain isoforms of the neuregulin-1 gene are required for maintenance of peripheral synapses | Q28511018 | ||
| Essential roles of Meltrin beta (ADAM19) in heart development | Q28512451 | ||
| Distinct signaling functions for Shc isoforms in the heart | Q28572126 | ||
| Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes | Q28572341 | ||
| Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt | Q28576264 | ||
| Isoflurane inhibits cardiac myocyte apoptosis during oxidative and inflammatory stress by activating Akt and enhancing Bcl-2 expression | Q28583535 | ||
| Multiple essential functions of neuregulin in development | Q28587914 | ||
| Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail | Q28590093 | ||
| ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice | Q28590176 | ||
| Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice | Q28591790 | ||
| Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy | Q28593656 | ||
| Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development | Q28593703 | ||
| Essential role for ADAM19 in cardiovascular morphogenesis | Q28594617 | ||
| Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4 | Q28609073 | ||
| Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice | Q29617498 | ||
| The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo | Q31805061 | ||
| 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples | Q33959693 | ||
| The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis | Q34183974 | ||
| Cloche, an early acting zebrafish gene, is required by both the endothelial and hematopoietic lineages. | Q34297652 | ||
| Characterization of the cell membrane-associated products of the Neuregulin 4 gene. | Q34660692 | ||
| Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling | Q35836843 | ||
| Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. | Q35951476 | ||
| Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells | Q35973421 | ||
| Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells | Q36136193 | ||
| Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets | Q36532167 | ||
| Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells | Q36609570 | ||
| Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer | Q36614997 | ||
| Cardiac developmental defects and eccentric right ventricular hypertrophy in cardiomyocyte focal adhesion kinase (FAK) conditional knockout mice | Q36638658 | ||
| Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure | Q36914725 | ||
| Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice | Q37195581 | ||
| Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2 | Q37490007 | ||
| Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development | Q37558638 | ||
| The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development | Q39677524 | ||
| Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. | Q39681091 | ||
| Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. | Q39870130 | ||
| Two-sided fluorescence resonance energy transfer for assessing molecular interactions of up to three distinct species in confocal microscopy | Q40043622 | ||
| Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines | Q40760846 | ||
| Requirement for neuregulin receptor erbB2 in neural and cardiac development | Q41269625 | ||
| Colocalization of the p185HER2 oncoprotein and integrin alpha 6 beta 4 in Calu-3 lung carcinoma cells | Q41451957 | ||
| Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes | Q41812527 | ||
| Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion | Q42803797 | ||
| Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. | Q42834861 | ||
| Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. | Q43504863 | ||
| Quercetin inhibits Shc- and phosphatidylinositol 3-kinase-mediated c-Jun N-terminal kinase activation by angiotensin II in cultured rat aortic smooth muscle cells | Q43741370 | ||
| ErbB2 is essential in the prevention of dilated cardiomyopathy. | Q43976647 | ||
| Importance of integrin signaling in myocyte growth and survival | Q44044670 | ||
| The breast proto-oncogene, HRGalpha regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland | Q44064300 | ||
| Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. | Q44273165 | ||
| Adenovirus-mediated overexpression of C-terminal Src kinase (Csk) in type I astrocytes interferes with cell spreading and attachment to fibronectin. Correlation with tyrosine phosphorylations of paxillin and FAK. | Q44454323 | ||
| Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects | Q44547164 | ||
| Myocyte contractile activity modulates norepinephrine cytotoxicity and survival effects of neuregulin-1β | Q44605071 | ||
| Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase | Q44734583 | ||
| Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion | Q45004044 | ||
| Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation | Q45042358 | ||
| Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy | Q45175895 | ||
| Anthracycline and trastuzumab in breast cancer treatment | Q45247438 | ||
| TACE is required for fetal murine cardiac development and modeling | Q46178015 | ||
| Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle | Q46465736 | ||
| Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro | Q46721802 | ||
| Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo | Q47223842 | ||
| Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts | Q47854934 | ||
| Isoform-specific expression and function of neuregulin. | Q48612811 | ||
| Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. | Q51202656 | ||
| Neuregulin receptors erbB2 and erbB4 in failing human myocardium -- depressed expression and attenuated activation. | Q51546024 | ||
| Notch1b and neuregulin are required for specification of central cardiac conduction tissue. | Q52025862 | ||
| Expression of multiple neuregulin transcripts in postnatal rat brains. | Q52212967 | ||
| NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. | Q52537021 | ||
| Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. | Q53846686 | ||
| Tumour biology: herceptin acts as an anti-angiogenic cocktail. | Q53976093 | ||
| Loss of beta1D-integrin function in human ischemic cardiomyopathy. | Q54565689 | ||
| HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. | Q54600558 | ||
| Adaptation phenomena of adult cardiac myocytes in culture. | Q54654453 | ||
| Strain-dependent epithelial defects in mice lacking the EGF receptor | Q58326927 | ||
| Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment | Q58352337 | ||
| Neuregulin in Cardiac Hypertrophy in Rats With Aortic Stenosis | Q60425242 | ||
| Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro | Q64381136 | ||
| Isolation and characterization of myocytes from the adult rat heart | Q67702458 | ||
| Isolation and characterization of human and rat cardiac microvascular endothelial cells | Q70595582 | ||
| The isolation of Ca2+-resistant myocytes from the adult rat | Q71306315 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 627-637 | |
| P577 | publication date | 2008-09-03 | |
| P1433 | published in | Experimental Cell Research | Q1524289 |
| P1476 | title | The role of Neuregulin-1beta/ErbB signaling in the heart | |
| P478 | volume | 315 |
| Q33559603 | A case of trastuzumab-associated cardiomyopathy presenting as an acute coronary syndrome: acute trastuzumab cardiotoxicity |
| Q29347286 | Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy |
| Q37078059 | Association of common variants in ERBB4 with congenital left ventricular outflow tract obstruction defects |
| Q36285897 | Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan |
| Q35427876 | Breast cancer therapy and cardiovascular risk: focus on trastuzumab |
| Q30251498 | Cancer drug related cardiotoxicity during breast cancer treatment |
| Q36887091 | Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. |
| Q35026889 | Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase. |
| Q47149101 | Cardiac Nonmyocyte Cell Functions and Crosstalks in Response to Cardiotoxic Drugs |
| Q45179221 | Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin |
| Q39344380 | Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab |
| Q35878459 | Cardiotoxicity of molecularly targeted agents |
| Q33907581 | Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future Directions |
| Q51348764 | Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches. |
| Q38717558 | Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity |
| Q37375662 | Critical role of nuclear calcium/calmodulin-dependent protein kinase IIdeltaB in cardiomyocyte survival in cardiomyopathy |
| Q47073947 | Dependence of cardiac trabeculation on neuregulin signaling and blood flow in zebrafish |
| Q27339919 | Differential Expression Levels of Integrin α6 Enable the Selective Identification and Isolation of Atrial and Ventricular Cardiomyocytes |
| Q39406865 | Downregulation of ErbB3 by Wnt3a contributes to wnt-induced osteoblast differentiation in mesenchymal cells |
| Q50992137 | ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. |
| Q38132645 | Emerging paradigms in cardiomyopathies associated with cancer therapies |
| Q37661237 | Emerging role of neuregulin as a modulator of muscle metabolism |
| Q34545577 | ErbB signaling in cardiac development and disease |
| Q35740039 | ErbB4 localization to cardiac myocyte nuclei, and its role in myocyte DNA damage response |
| Q27348830 | Erbb2 is required for cardiac atrial electrical activity during development |
| Q38834995 | Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity |
| Q37288691 | Gene transfer of human neuregulin-1 attenuates ventricular remodeling in diabetic cardiomyopathy rats |
| Q33747967 | Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system |
| Q28394350 | IgG-Containing Isoforms of Neuregulin-1 Are Dispensable for Cardiac Trabeculation in Zebrafish |
| Q92052896 | Implications of Autophagy and Oxidative Stress in Trastuzumab-Mediated Cardiac Toxicities |
| Q38546114 | Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. |
| Q37189988 | Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes |
| Q39129349 | Mechanisms of Cardiomyocyte Proliferation and Differentiation in Development and Regeneration |
| Q44740067 | Mesenchymal stem cells from rat olfactory bulbs can differentiate into cells with cardiomyocyte characteristics |
| Q36930808 | Methylglyoxal-Induced Endothelial Cell Loss and Inflammation Contribute to the Development of Diabetic Cardiomyopathy |
| Q36802746 | MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy |
| Q28296128 | Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale |
| Q38483371 | Neuregulin 1-alpha regulates phosphorylation, acetylation, and alternative splicing in lymphoblastoid cells |
| Q37738659 | Neuregulin signaling and heart failure |
| Q54196391 | Neuregulin-1 increases connexin-40 and connexin-45 expression in embryonic stem cell-derived cardiomyocytes. |
| Q38200558 | Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure |
| Q28295209 | Neuregulin-1/ErbB signaling and chronic heart failure |
| Q42969095 | Neuregulin-1beta1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes |
| Q27334101 | Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors |
| Q53193638 | Neuregulin-1β promotes glucose uptake via PI3K/Akt in neonatal rat cardiomyocytes. |
| Q39673715 | Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells |
| Q57176905 | New Myocyte Formation in the Adult Heart: Endogenous Sources and Therapeutic Implications |
| Q88232455 | Optimal Objective-Based Experimental Design for Uncertain Dynamical Gene Networks with Experimental Error |
| Q47681122 | Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy |
| Q57805172 | Paving new paths for neuregulin-1-assisted cardiac regenerative medicine. Focus on “Improving murine embryonic stem cell differentiation into cardiomyocytes with neuregulin-1: differential expression of microRNA” |
| Q30251531 | Potential new drug treatments for congestive heart failure |
| Q38786052 | Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments |
| Q38606067 | Systems biology approaches to adverse drug effects: the example of cardio-oncology |
| Q38201344 | The EGFR family: not so prototypical receptor tyrosine kinases |
| Q26743433 | The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy |
| Q34776866 | The effects of neuregulin on cardiac Myosin light chain kinase gene-ablated hearts |
| Q36630478 | The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics. |
| Q36042588 | The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation |
| Q90903328 | The zinc finger protein Zfpm1 modulates ventricular trabeculation through Neuregulin-ErbB signalling |
| Q35207833 | Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats |
| Q64065124 | Toward Regeneration of the Heart: Bioengineering Strategies for Immunomodulation |
| Q35532125 | Trastuzumab-induced cardiac dysfunction: A 'dual-hit' |
| Q38503419 | Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations |
| Q37871555 | What chick and mouse models have taught us about the role of the endocardium in congenital heart disease |
| Q33710767 | c-Cbl inhibition improves cardiac function and survival in response to myocardial ischemia |
Search more.